Investor Relations

Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.


Copyright West LLC. Minimum 15 minutes delayed.

Events

December 4, 2019 at 9:00 AM EST
Print Page
E-mail Alerts
RSS
Investor Contacts